Volatile Organic Compounds as Breath Biomarkers in Squamous Oesophageal Neoplasms

Launched by IMPERIAL COLLEGE LONDON · Dec 5, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to detect a type of cancer called Oesophageal Squamous Cell Carcinoma (OSCC), which affects the food pipe and can be very serious if found late. Currently, there are no national screening tests for this cancer, and the only method available is an endoscopy, which can be uncomfortable and is not always easy to access. The researchers want to develop a simple breath test that can help identify signs of this cancer early on. This test works by detecting tiny molecules, called volatile organic compounds (VOCs), that the cancer releases in a person’s breath. If someone tests positive for these compounds, they will be referred for an urgent endoscopy, while those who test negative can feel reassured.

To take part in this trial, participants need to be between 65 and 74 years old and either have confirmed OSCC or be undergoing an endoscopy for other upper gastrointestinal symptoms. They cannot have received any treatment for OSCC or have certain other health conditions. The trial is currently recruiting participants, and the goal is to make early cancer detection easier and less invasive, which could lead to better outcomes for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria: Participants with all the following characteristics will be eligible for inclusion in the study:
• • 1. Cancer cohort (n=259): Patients with treatment naïve, histopathology confirmed OSCC.
• 2. Control cohort (n=259): Patients who have undergone or are undergoing an endoscopy (OGD) as part of their investigation for upper GI symptoms and are found to have either:
• • A normal upper gastrointestinal tract
• • Benign upper gastrointestinal disease
• Exclusion Criteria: Participants with the following characteristics will not be eligible for inclusion in the study:
• • 1. Received some form of treatment (chemotherapy, radiotherapy, immunotherapy, endoscopic resection, or surgery) for OSCC
• • 2. History of another cancer in the last five years
• • 3. Non-squamous cell oesophageal cancer
• • 4. Barrett's oesophagus (with or without dysplasia)
• • 5. Previous oesophageal or gastric resection
• • 6. Unable to provide written consent or lack capacity.
• • 7. Pregnant women